Skip to main content
. Author manuscript; available in PMC: 2016 Oct 18.
Published in final edited form as: Nat Biotechnol. 2016 Apr 18;34(5):539–546. doi: 10.1038/nbt.3527

Figure 4.

Figure 4

REVEALER results for the drug sensitivity to a MEK-inhibitor example. The target is the MEK-inhibitor PD0325901 sensitivity profile in cancer cell lines and no seed feature (NULLSEED). REVEALER iterates 3 times and identifies BRAF, KRAS and NRAS mutations, all well-known oncogenes upstream of MEK, as complementary “causes” of MEK-inhibitor sensitivity.